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Summary
Antibodies (Abs) to RNA- and DNA-containing autoan-
tigens are characteristic of systemic lupus erythema-
tosus (SLE). We showed previously that Toll-like
receptor (TLR) 9, recognizing DNA, is required for the
spontaneous generation of DNA autoantibodies, but
not for the development of lupus nephritis in suscepti-
ble mice. We report that lupus-prone mice deficient in
TLR7, a receptor for ssRNA, failed to generate Abs to
RNA-containing antigens (Ags) such as Smith (Sm)
Ag. TLR9 and TLR7 also had dramatic effects on clini-
cal disease in lupus-prone mice. In the absence of
TLR9, autoimmune disease was exacerbated, lympho-
cytes and plasmacytoid DCs were more activated, and
serum IgG and IFN-a were increased. In contrast,
TLR7-deficient mice had ameliorated disease, de-
creased lymphocyte activation, and decreased serum
IgG. These findings reveal opposing inflammatory
and regulatory roles for TLR7 and TLR9, despite simi-
lar tissue expression and signaling pathways. These
results have important implications for TLR-directed
therapy of autoimmune disease.
Introduction
Production of autoantibodies is a cardinal feature of sys-
temic lupus erythematosus (SLE) (Tan et al., 1982). Dis-
ease-related autoantibodies in SLE focus on particular
targets, such as double-stranded DNA (dsDNA) and
chromatin and RNA-containing Ags such as Smith
(Sm) Ag and ribonucleoprotein (RNP) or ribosomal com-
ponents (Egner, 2000; Muro, 2005). The correlation of
DNA, Sm, and RNP Abs with disease activity and distinct
clinical features of SLE highlights the potential patho-
genic roles of these autoantibodies (Alba et al., 2003;
Kirou et al., 2005). Despite long-standing knowledge of
the specificity of the autoimmune response in SLE, little
is known about why autoantibodies are focused on
these particular targets (Plotz, 2003).
An important new insight in this area was the implica-
tion of Toll-like receptors (TLRs) in autoreactive B cell
stimulation. Studies showing that rheumatoid factor B
cells were stimulated in vitro in a DNase-sensitive and
MyD88-dependent way led to the proposal that TLR9,
*Correspondence: mark.shlomchik@yale.edua receptor for CpG DNA, is required to activate these
B cells through anti-chromatin immune complexes
(Leadbetter et al., 2002). This was extended to chroma-
tin-specific B cells, which can be activated by the dual
ligation of the Ag-specific BCR on the cell surface and
TLR9 in intracellular compartments (Viglianti et al.,
2003). Moreover, analogous data indicate that TLR7,
a receptor for ssRNA, is required for optimal in vitro pro-
liferation of B cells specific for RNA-containing Ags, thus
potentially explaining a second major class of autoanti-
bodies (Lau et al., 2005).
Until recently, the in vivo significance of these findings
was unknown. The fact that TLR9 and TLR7 are ex-
pressed on B cells, macrophages, plasmacytoid DCs
(pDCs), and (in mice) myeloid DCs (mDCs) (Edwards
et al., 2003; Iwasaki and Medzhitov, 2004) could lead
to a potentially complicated situation in vivo, particularly
because TLR signaling differs in pDCs and other cell
types (Honda et al., 2005). Indeed, a role for TLRs in
stimulating dendritic cells (DCs) in autoimmune disease
was suggested by the finding that DCs secrete inflam-
matory cytokines via a TLR9- or TLR7-dependent mech-
anism upon stimulation with nucleic acid-containing im-
mune complexes (Boule et al., 2004; Means et al., 2005;
Savarese et al., 2006). By using an F2 breeding strategy
to cross MRL/Mplpr/lpr with B6/129 TLR9-deficient mice,
we initially found that TLR9 was required for the produc-
tion of chromatin Abs in vivo (Christensen et al., 2005).
This validated the notion that TLRs, presumably recog-
nizing self-Ags, played a key role in systemic auto-
immunity. We also noted that despite the lack of anti-
chromatin, clinical disease was not ameliorated, and
certain parameters of immune activation were actually
greater in Tlr92/2 than in wild-type mice (Christensen
et al., 2005). Subsequently, an effect of TLR9 in regulat-
ing autoimmune disease was reported in a study of
a small number of backcrossed MRL/Mp mice (Wu
and Peng, 2006). However, with ELISA-based assays,
these investigators did not find an effect of TLR9 on
DNA Abs (Wu and Peng, 2006). A third study, using
a model in which all B cells express a high-affinity anti-
DNA H chain in the context of FcgRIIB deficiency, re-
ported that TLR9 was required for the production of
IgG2a/2b DNA Abs, although these investigators did
not assess clinical disease or total anti-DNA and anti-
chromatin (Ehlers et al., 2006). Thus, the effect of TLR9
on DNA and chromatin Abs, as well as various parame-
ters of immune activation and clinical disease, remains
controversial.
Antibodies to DNA and chromatin represent one class
of dominant autoantibodies in human and murine lupus;
Abs to RNA-containing molecules are another. Although
Abs to RNA-related Ags are not as common as anti-
chromatin, they tend to be associated with more severe
disease in lupus patients (Kirou et al., 2005). We previ-
ously reported that neither TLR3 nor TLR9 were required
for production of Sm Abs in vivo (Christensen et al.,
2005). Since all classes of nuclear Abs were absent in
MyD88-deficient autoimmune-prone mice, however, it
seems likely that anti-Sm and other RNA Abs are
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418controlled by another TLR (Lau et al., 2005). Recent work
has implicated TLR7 in the pathogenesis of SLE (Pisit-
kun et al., 2006; Savarese et al., 2006; Subramanian
et al., 2006; Vollmer et al., 2005), but whether this recep-
tor is required for autoantibody formation and whether it
affects clinical disease progression in vivo have not
been determined.
Here we first clarify the situation with regard to TLR9
and autoimmune disease, in light of the three conflicting
reports, by performing extensive analysis of mice in
which the disrupted TLR9 allele was backcrossed to
the autoimmune MRL/Mplpr/lpr genetic background.
These data support and extend our original findings in
autoimmune F2 hybrid mice, particularly the clear effect
on chromatin Abs (Christensen et al., 2005). We confirm
that MRL/Mplpr/lpr mice lacking TLR9 developed more
severe clinical disease and show that it leads to early
mortality. In addition, we report that TLR7 was required
for the generation of autoantibodies to RNA-containing
Ags in vivo. Surprisingly, despite the similarities be-
tween TLR7 and TLR9 in terms of sequence, specificity,
tissue expression, and signaling, TLR7 had the opposite
effect on disease from TLR9. These findings together
account for the targeting of the major classes of auto-
antibodies in SLE and have important implications for
therapeutic strategies based on manipulating TLR rec-
ognition and signaling.
Results
Impaired Generation of Antibodies to DNA Ags
in TLR9-Deficient Mice
In order to analyze the effects of TLR9 on murine SLE in
a controlled genetic experiment, Tlr9+/2 hybrid mice
were backcrossed eight generations to lupus-prone
MRL/Mplpr/lpr mice (Cohen and Eisenberg, 1991). Back-
crossed heterozygotes were then intercrossed, and
wild-type littermates were used as controls for Tlr92/2
MRL/Mplpr/lpr mice. We used the fluorescent ANA assay
as a sensitive detection method for Abs to both RNA-
containing and DNA-containing autoantigens (Emlen
and O’Neill, 1997; Muro, 2005; Tan et al., 1982). Typical
of MRL/Mplpr/lpr sera, the majority of Tlr9+/+ sera pro-
duced a homogenous nuclear ANA pattern, correspond-
ing to DNA and chromatin autoantibodies (Figures 1A
and 1B). Moreover, 25 of 26 wild-type mice produced
specific chromatin Abs, as determined by equatorial
staining of chromosomes in metaphase cells (Figures
1A and 1C). In contrast, none of the sera from 21 Tlr92/2
mice produced homogenous staining, and only two
mice generated Abs capable of binding to mitotic chro-
matin (Figures 1A–1C, p < 0.0001). These results confirm
our earlier findings in F2 mice, demonstrating severe im-
pairment in the generation of Abs to native DNA and
chromatin in the absence of TLR9.
Staining patterns generated by TLR9-deficient sera
revealed a potential shift in repertoire specificity. Al-
though an equivalent fraction of sera from both groups
produced speckled nuclear staining patterns (indicative
of Abs to RNA splicing complexes such as Sm and RNP),
sera from 15 of 21 Tlr92/2 mice, and none of the wild-
type mice, produced a primarily cytoplasmic pattern
(Figures 1A and 1B, p < 0.0001 for comparison of patterndistribution between Tlr9+/+ and Tlr92/2). Autoanti-
bodies to cytoplasmic RNA complexes are common in
SLE sera and lead to fine granular or homogenous cyto-
plasmic staining of ANA substrates (Lau et al., 2005;
Muro, 2005), such as was observed in Tlr92/2 sera (Fig-
ure 1A, bottom right). Although cytoplasmic staining can
also be produced by Abs to organelles such as endo-
somes, the Golgi apparatus, or mitochondria, these
Abs stain discrete regions of the cytoplasm in a charac-
teristic pattern (Muro, 2005) that was not observed in
sera from Tlr92/2 mice (Figure 1A and data not shown).
Thus, although TLR9-deficient and wild-type sera both
produced nuclear speckled patterns characteristic of
Sm and RNP Abs, only TLR92/2 mice generated Abs re-
acting with cytoplasmic Ags that may include RNA.
The lack of homogenous nuclear and mitotic chroma-
tin staining patterns in Tlr92/2 sera indicated a block in
the generation of Abs to DNA-containing Ags. Because
of the high specificity of Crithidia luciliae immunofluo-
rescence in the detection of Abs to dsDNA (Isenberg
et al., 1987), we used this assay to confirm our ANA find-
ings. Tlr92/2 sera showed a substantial decrease in Abs
binding the dsDNA of the C. luciliae kinetoplast (Fig-
ure 1D, p < 0.0001). This decrease was highly significant
but did not represent a complete block in dsDNA Ab pro-
duction, because some Tlr92/2 samples specifically
stained the kinetoplast, albeit with lower intensity. This
low level of dsDNA Ab production in Tlr92/2 mice was
in contrast to the almost complete absence of Abs to na-
tive DNA and chromatin as determined by the ANA as-
say. It is probable that this difference reflects the nature
of endogenous DNA, which exists in a macromolecular
chromatin complex. Indeed, many autoantibodies in
SLE preferentially bind to continuous DNA-histone
epitopes rather than isolated dsDNA, suggesting that
chromatin is the physiologically relevant autoantigen
(Losman et al., 1992).
We used enzyme-linked immunosorbent assays
(ELISA) to quantitate the decrease in Abs to DNA-con-
taining Ags in Tlr92/2 sera. An anti-nucleosome ELISA,
in which the detection Ag was the combination of his-
tones and dsDNA, demonstrated an order-of-magnitude
decrease in specific DNA Abs in Tlr92/2 sera (Figure 1E,
p < 0.0001). When we employed a standard ELISA for
dsDNA in which the detection Ag was the combination
of poly-L-lysine and dsDNA, however, there was not
a significant decrease in Tlr92/2 sera (Figure 1F). These
apparently conflicting findings illustrate two points.
First, they highlight the low specificity of ELISA-based
assays, which are known to be susceptible to high false
positive rates in the detection of DNA Abs (Emlen and
O’Neill, 1997; Isenberg et al., 1987). Second, they again
implicate the chromatin complex of DNA and histones
as the endogenous Ag recognized by TLR9 in SLE, while
Abs binding to purified dsDNA may represent cross-
reactivity with other nucleic acid autoantigens, or
charge-based nonspecific association. The anti-dsDNA
ELISA appeared to be particularly susceptible to non-
specific binding, because values from this assay were
significantly correlated with total IgG (p = 0.0163), while
antinucleosome values were not (see Figure S1 in the
Supplemental Data available online).
We also determined amounts of Sm Abs in Tlr92/2
sera. Unlike Abs to DNA-containing Ags, we did not
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419Figure 1. Impaired Generation of Abs to DNA Ags in TLR9-Deficient Mice
(A) ANAs from Tlr9+/+ sera are shown at top (left, homogenous nuclear pattern; right, speckled nuclear pattern), and Tlr92/2 sera at bottom (left,
speckled nuclear pattern; right, cytoplasmic pattern). White arrows indicate cells in metaphase that demonstrate positive (top, Tlr9+/+) or neg-
ative (bottom, Tlr92/2) staining of mitotic chromatin.
(B) Serum ANAs were classified as either nuclear homogenous, nuclear speckled, or cytoplasmic staining patterns. Black bars indicate Tlr9+/+
(n = 26), and white bars indicate Tlr92/2 (n = 21) sera.
(C) As in (B), but ANAs were classified as either positive or negative for mitotic chromatin staining.
(D) dsDNA Abs in Tlr9+/+ (black symbols, n = 26) and Tlr92/2 (white symbols, n = 21) sera detected by C. luciliae immunofluorescence. Intensity of
staining C. luciliae kinetoplast DNA was scored from 0 to 4.
(E–G) Nucleosome (E), dsDNA (F), and Sm-RNP (G) Abs determined by ELISA in Tlr9+/+ (black symbols, n = 26) and Tlr92/2 (white symbols, n = 21)
sera. Bars represent median values (E–G). ***p < 0.0001 by either Chi square analysis (B), Fisher’s exact test (C), or Mann-Whitney U test (D and E).detect a significant difference in Abs to Sm or the Sm-
RNP complex between wild-type and Tlr92/2 mice
(Figure 1G and data not shown). Of note, however, is
that Tlr92/2mice appeared to have an elevated baseline
level of anti-Sm-RNP (Figure 1G), suggesting that, had
these mice survived longer, they may have developed
higher anti-Sm titers, analogous to our earlier findings
in a cohort of older Tlr92/2 F2 mice (Christensen et al.,
2005).TLR9 Regulates Plasmacytoid Dendritic Cell
Activation in SLE
Because TLR9 is expressed by murine plasmacytoid
and myeloid DCs (Edwards et al., 2003), we hypothe-
sized that the lack of this receptor could influence the
function of DC subsets in autoimmune disease. By iden-
tifying pDCs as CD11cint pDCA-1+ cells (Krug et al.,
2004), we found that splenic pDCs from Tlr92/2mice ap-
peared to be more activated than wild-type pDCs based
Immunity
420Figure 2. TLR9 Regulates pDC Activation in
SLE
(A) Left: splenic pDCs (CD11cint pDCA-1+)
and myeloid DCs (CD11chi pDCA-12) were
identified by FACS. Right: MHC class II ex-
pression in pDCs (left) and myeloid DCs
(right) from Tlr9+/+ (dashed line) and Tlr92/2
(solid line) mice. Numbers on gates indicate
percentage of cells.
(B and C) Expression of MHC class II, CD80,
and CD86 in pDCs (B) and myeloid DCs (C)
from Tlr9+/+ (black bars, n = 26) and Tlr92/2
(white bars, n = 21) mice. Data are presented
as mean 6 SEM.
(D) IFN-a levels in serum from Tlr9+/+ (black
symbols, n = 26) and Tlr92/2 (white symbols,
n = 21) mice. Limit of detection was 0.1 ng/ml.
Two of 26 Tlr9+/+ and 11 of 21 Tlr92/2 sera had
IFN-a > 0.1 ng/ml. Bars represent median
values. *p < 0.05; **p < 0.01; ***p < 0.0001
by Mann-Whitney U test.on the increased expression of MHC class II (Figures 2A
and 2B, p < 0.0001). Plasmacytoid DCs from Tlr92/2
mice also had increased expression of the activation
markers CD80 and CD86 (Figure 2B, p = 0.0007 and
0.0002, respectively). This effect was specific to pDCs;
conventional, CD11chi myeloid DCs from both strains
had similar expression of these molecules (Figures 2A
and 2C).
The increased expression of activation markers by
pDCs in Tlr92/2 mice suggested a specific effect of
TLR9 on pDC function in SLE. Because a major func-
tional consequence of pDC activation by TLRs is the se-
cretion of type I interferons (IFN-I), we determined the
serum concentration of IFN-a in Tlr92/2 mice. In agree-
ment with the increased pDC activation state, we found
that more than half of Tlr92/2 sera had detectable
amounts of IFN-a, compared with only 2 of 26 wild-
type sera (Figure 2D, p = 0.0009 by Fisher’s exact test).
Increased Immune Activation in TLR9-Deficient Mice
Having observed the clear effects of TLR9 deficiency on
autoantibody production and pDC activation, we then
determined whether the absence of this receptor had
a significant impact on the manifestation of clinical auto-
immune disease, as had been suggested by previous
studies (Christensen et al., 2005; Wu and Peng, 2006).
We found that Tlr92/2 mice had a significant increase
in the incidence and severity of autoimmune skin dis-
ease compared to wild-type littermates (Figure 3A, p =
0.0136). Concordant with this were increased lymph-
adenopathy and splenomegaly in Tlr92/2 mice (Fig-
ure 3B, p = 0.0043 and 0.0023, respectively).
Increased spleen and lymph node weight in MRL/
Mplpr/lpr mice is accompanied by accumulation of lym-
phocytes expressing an activated phenotype in these
organs (Cohen and Eisenberg, 1991). As expected
from their increased spleen and lymph node weight,
Tlr92/2 mice had an increased number of CD4+ helper
T cells as well as a 3-fold increase in the number of
CD42 CD82 double-negative T cells in the spleen (Fig-
ure 3C, p = 0.0096 and 0.002, respectively). This aberrant
population of double-negative T cells is thought to arise
from the inability to delete activated cells in Fas-
deficient animals (Cohen and Eisenberg, 1991). Analysisof T cell activation status in the lymph node revealed a
similar effect of TLR9 deficiency. Tlr92/2mice had fewer
naive phenotype CD4+ cells, with a significant increase
in activated CD44+ cells (Figure 3D, p = 0.0001). Similar
results were observed in the spleen (data not shown).
Finally, deficiency of TLR9 also affected global B cell ac-
tivation. Splenic B cells from Tlr92/2mice had increased
expression of the activation markers CD44 and CD69
(Figure 3E, p = 0.0002 and 0.0333, respectively).
As another measure of global B cell activation, we de-
termined total amounts of serum IgG. Tlr92/2 sera had
increased concentrations of every IgG isotype, but the
most prominent increases were in IgG2a and IgG3,
which were 2-fold greater than in wild-type sera (Fig-
ure 3F, p = 0.0038 for IgG1, 0.0043 for IgG2a, 0.0006
for IgG2b, and p < 0.0001 for IgG3). Interestingly, the iso-
types profoundly affected by the absence of TLR9 are
the immunoglobulin isotypes frequently associated
with inflammation and autoimmunity (Nimmerjahn and
Ravetch, 2005). Indeed, IgG3 has been shown to play
a central role in the development of nephritis in MRL/
Mplpr/lpr mice (Takahashi et al., 1991). Taken together,
these data indicate that the genetic absence of TLR9
led to increased disease activity and global immune ac-
tivation in MRL/Mplpr/lpr mice.
Accelerated Lupus Nephritis and Mortality
in the Absence of TLR9
The definitive measure of end-organ pathology in SLE is
the presence of lupus nephritis. In agreement with other
evidence of increased disease activity, TLR9-deficient
mice developed exacerbated kidney disease. We ob-
served increased glomerular size, cellularity, and protein
deposition in Tlr92/2 kidney sections, leading to a histo-
logic glomerulonephritis score that was significantly
greater than wild-type littermates (Figures 4A and 4B,
p = 0.0024). Kidneys from MRL/Mplpr/lpr mice also show
a characteristic interstitial infiltration of lymphocytes
and monocytes, primarily centered around major vessels,
and occasionally invading the cortical parenchyma. There
was a trend toward increased severity of interstitial infil-
trates inTlr92/2mice, but it did not reach statistical signif-
icance (Figure 4B). However, the composite score of both
interstitial and glomerular disease revealed a significant
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(Figure 4C, p = 0.0029).
Although we observed an increase in nearly every
marker of disease severity in autoimmune Tlr92/2
mice, it remained unclear whether these disease
markers truly affected mortality. We therefore allowed
a second cohort of Tlr9+/+, Tlr9+/2, or Tlr92/2 MRL/
Mplpr/lpr littermates to develop spontaneous disease,
and we monitored them without intervention until the
time of death or irreversible morbidity. We found that
TLR9-deficient mice had accelerated mortality relative
to wild-type controls; median survival was reduced
from 25.1 weeks in Tlr9+/+ mice and 24.9 weeks in
Tlr9+/2 mice to 16.4 weeks in Tlr92/2 mice (Figure 4D,
p = 0.0002 and 0.0047 for comparison of Tlr92/2 with
Figure 3. Increased Immune Activation in TLR9-Deficient Mice
Tlr9+/+ (black bars, n = 26) and Tlr92/2 (white bars, n = 21) mice were
assayed for various parameters of disease activity and immune ac-
tivation.
(A) Severity of skin disease.
(B) Weight of spleens and the two largest axillary lymph nodes.
(C) Numbers of splenic CD4+ T cells, CD8+ T cells, CD42/CD82 dou-
ble-negative T cells (DNTC), and B cells.
(D) CD44 expression by lymph node CD4+ T cells.
(E) Expression of CD44 and CD69 on splenic B cells.
(F) Serum IgG isotype concentrations. Data are presented as mean6
SEM. *p < 0.05; **p < 0.01; ***p < 0.0001 by Mann-Whitney U test.Tlr9+/+ and Tlr9+/2, respectively). There was no differ-
ence in survival between wild-type and Tlr9+/2 hetero-
zygote mice, suggesting that a single copy of TLR9 is
sufficient to regulate fatal SLE in this model.
Association of Disease Severity with Antibodies
to RNA Ags
Abs to RNA-containing Ags have been associated with
disease severity in human SLE patients (Alba et al.,
2003; Kirou et al., 2005; Migliorini et al., 2005). Because
we observed a shift in autoantibody specificity and ex-
acerbated disease in Tlr92/2 mice, we determined
Figure 4. Accelerated Lupus Nephritis and Mortality in TLR9-
Deficient Mice
(A) Representative PAS-stained Tlr9+/+ (left) and Tlr92/2 (right) glo-
meruli.
(B) Interstitial and glomerular renal disease were scored from 0 to 4
for Tlr9+/+ (black symbols, n = 26) and Tlr92/2 (white symbols, n = 21)
mice.
(C) As in (B), but the sum of interstitial and glomerular scores for each
mouse was plotted to determine composite renal disease.
(D) Tlr9+/+ (blue line, n = 61), Tlr9+/2 (black dashed line, n = 29), and
Tlr92/2 (red line, n = 44) mice were observed until the time of death.
**p < 0.01 by Mann-Whitney U test (B and C) or logrank test (D).
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ated with disease severity. Tlr9+/+ and Tlr92/2mice were
grouped based on the presence of Sm or Sm-RNP Abs.
The presence of Abs to RNA Ags was indeed correlated
with increased immune activation in our cohort. In both
the wild-type and Tlr92/2 groups, mice with Sm-RNP
Abs exhibited an increase in MHC class II expression
by pDCs compared to mice without anti-Sm-RNP (Fig-
ure S2A). In Tlr92/2 mice, higher titers of RNA-related
Abs were also associated with exacerbated skin disease
(Figure S2B). We also observed increased splenic CD4+
T cell activation and interstitial lymphocytic infiltrates in
the kidneys of TLR92/2mice with Sm-RNP Abs (data not
shown).
Impaired Generation of Antibodies to RNA Ags
in TLR7-Deficient Mice
Analogous to TLR9, we generated TLR7-deficient auto-
immune-prone mice by backcrossing three to six gener-
ations to MRL/Mplpr/lpr mice. Because TLR7 is located
on the X chromosome, we compared male Tlr72/y mice
with male Tlr7+/y littermates. Analysis of ANA staining
by Tlr72/y or wild-type sera revealed patterns typical of
SLE. The majority of mice in both groups produced
DNA Abs, as determined by homogenous nuclear stain-
ing, and all serum samples contained chromatin Abs
(Figures 5A–5C). There were, however, subtle differ-
ences in ANA staining patterns derived from wild-type
and Tlr72/y mice. Sera from some wild-type mice pro-
duced speckled staining in the absence of any other pat-
terns, indicative of specific Abs to Sm and RNP. Tlr72/y
sera, in contrast, produced speckled patterns that were
obscured by superimposed homogenous staining (Fig-
ure 5A). 7 of 36 wild-type sera produced this ‘‘pure’’
speckled pattern, which was not observed in any of 35
Tlr72/y sera (p = 0.0113 by Fisher’s exact test). This sug-
gested impairment in the generation of Abs to RNA com-
plexes in Tlr72/y mice.
Consistent with the ANA staining patterns, the gener-
ation of high-titer Sm Abs was blocked in Tlr72/y mice
(Figure 5D, p = 0.0309). However, because Sm Abs occur
with a relatively low prevalence (Cohen and Eisenberg,
1991; Migliorini et al., 2005), only 6 of 36 Tlr7+/y sera
had high titers of anti-Sm, in addition to 3 sera with inter-
mediate levels, compared with 0 of 35 Tlr72/y samples.
We therefore also used a more sensitive Ag, the U1 small
nuclear ribonucleoprotein complex, composed of both
Sm and RNP protein Ags, to detect Abs to RNA-contain-
ing Ags (Migliorini et al., 2005). The relative decrease in
these Abs to RNA Ags in Tlr72/y mice was highly signif-
icant (Figure 5E, p = 0.0035). This blockade of autoanti-
body production in Tlr72/y mice was specific for Abs to
RNA-containing Ags, as shown by the fact that there
was no decrease in DNA or chromatin Abs as detected
by either ANA or ELISA-based assays (Figures 5A–5C,
5F, and 5G).
Reduced Immune Activation in TLR7-Deficient Mice
There was a significant decrease in both lymph node
and spleen weight in Tlr72/y mice compared to wild-
type littermates (Figure 6A, p = 0.0005 and 0.0295,
respectively). The decrease in spleen weight among
Tlr72/y mice was paralleled by a decrease in the accu-
mulation of double-negative T cells (Figure 6B, p =0.0155). Similarly, Tlr72/y mice had a decreased propor-
tion of CD4+ T cells expressing CD44, both in the lymph
node (Figure 6C, p = 0.0009) and the spleen (data not
shown). Lack of TLR7 also inhibited general B cell acti-
vation, as indicated by the fact that CD44 expression
was decreased in splenic B cells from Tlr72/y mice, al-
though CD69 expression was unaffected (Figure 6D,
p = 0.0026 for CD44). Serum IgG levels, another marker
of B cell activation, were decreased in Tlr72/y mice, but
only for IgG2a and IgG3 (Figure 6E, p < 0.0001 for both),
the two isotypes most elevated in Tlr92/2 serum. Inter-
estingly, these two immunoglobulin isotypes are most
potently induced by IFN-I (Le Bon et al., 2001).
Unlike TLR9, which regulated pDC activation, TLR7
appeared to promote pDC activation in the context of
SLE. Plasmacytoid DCs from Tlr72/y mice exhibited a
more immature phenotype, with decreased expression
of MHC class II (Figures 6F and 6G, p = 0.0144), although
expression of CD80 and CD86 were unaffected (Fig-
ure 6G). The activation state of myeloid DCs appeared
unaffected by the absence of TLR7 (Figures 6F and
6H). Although TLR7 deficiency inhibited the activation
of pDCs, it did not completely prevent systemic IFN-I
production, as shown by the fact that a small subset of
sera from both Tlr7+/y and Tlr72/y mice contained de-
tectable levels of IFN-a (data not shown). These findings
correlate with the reciprocal effects of TLR7 and TLR9
on serum IgG levels and suggest the possibility of B
cell-pDC interactions in the pathogenesis of autoanti-
body formation.
Ameliorated Clinical Disease in the Absence of TLR7
The effects of TLR7 deficiency were also evident in the
kidney. Tlr72/y mice appeared to have ameliorated renal
disease, with decreased glomerular protein deposition
and preserved glomerular structure (Figure 7A). Al-
though the trend toward decreased severity of individual
parameters of nephritis did not reach statistical signifi-
cance (Figure 7B), the composite score of renal disease
was significantly reduced in Tlr72/y mice (Figure 7C, p =
0.0109). In addition, there was very little skin disease in
Tlr72/y mice at 16 weeks of age. Although skin disease
was evident in Tlr7+/y mice, it occurred with a relatively
low frequency such that the difference between the
two groups did not reach statistical significance (p =
0.0878, data not shown). All 20 mice in each group sur-
vived to analysis at 16 weeks of age; a formal analysis
of survival in a new cohort is ongoing. Overall, the effects
of TLR7 deficiency on clinical disease were less pro-
nounced than the effects of TLR9 deficiency. This could
be due to subtle differences between the TLR7 and
TLR9 cohorts, or could be a result of the overwhelming
predisposition toward autoimmune disease in MRL/
Mplpr/lpr mice, which is more prone to exacerbation
than inhibition.
Discussion
The findings presented here help to clarify the contro-
versy in the literature regarding the role of Toll-like
receptors and innate immunity in the generation of spe-
cific autoantibodies in SLE and the contribution of auto-
antibodies and TLRs to clinical disease manifestations.
We found that the requirement for TLR9 in the
Opposing Roles of TLR7 and TLR9 in Murine Lupus
423Figure 5. Impaired Generation of Abs to RNA Ags in TLR7-Deficient Mice
(A) ANAs from Tlr7+/y sera are shown at top (left, homogenous nuclear pattern; right, speckled nuclear pattern), and Tlr72/y sera at bottom (left,
homogenous nuclear pattern; right, speckled nuclear pattern). Speckled patterns in Tlr72/y sera were a mix of speckled staining with superim-
posed homogenous staining. White arrows indicate cells in metaphase that demonstrate positive staining of mitotic chromatin.
(B) Serum ANAs were classified as either nuclear homogenous, nuclear speckled, or cytoplasmic staining patterns. Black bars indicate Tlr7+/y
(n = 36), and white bars indicate Tlr72/y (n = 35) sera.
(C) As in (B), but ANAs were classified as either positive or negative for mitotic chromatin staining.
(D and E) Sm (D) and Sm-RNP (E) Abs determined by ELISA in Tlr7+/y (black symbols, n = 36) and Tlr72/y (white symbols, n = 35) sera.
(F and G) Nucleosome (F) and dsDNA (G) Abs determined by ELISA in Tlr7+/y (black symbols, n = 20) and Tlr72/y (white symbols, n = 20) sera. Bars
represent median values (D–G). *p < 0.05; **p < 0.01 by Mann-Whitney U test.production of autoantibodies to DNA-containing Ags,
first observed in lupus-prone F2 mice (Christensen
et al., 2005), also applied to Tlr92/2 mice fully back-
crossed to the MRL/Mplpr/lpr strain. This is in contrast
to a reported increase in anti-DNA titers in TLR9-
deficient MRL/Mp mice (Wu and Peng, 2006). These
conflicting findings can most likely be attributed to the
assays used to detect DNA Abs. Wu and Peng used an
ELISA-based assay to determine anti-DNA titers, de-spite the documented lack of specificity of such assays
for autoantibodies in the context of SLE (Emlen and
O’Neill, 1997; Isenberg et al., 1987) (Figure S1). More-
over, this study, with a limited number of six mice per
group, did not adequately document immunofluores-
cent ANA patterns or C. luciliae immunofluorescence
with Tlr92/2 sera (Wu and Peng, 2006). By using these
more specific assays in Tlr92/2 mice of a homogenous
and defined genetic background, we clearly show that
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424Figure 6. Decreased Immune Activation in TLR7-Deficient Mice
Tlr7+/y (black bars, n = 20) and Tlr72/y (white bars, n = 20) mice were assayed for various parameters of disease activity and immune activation.
(A) Weight of spleens and the two largest axillary lymph nodes.
(B) Numbers of splenic CD4+ T cells, CD8+ T cells, CD42/CD82 double-negative T cells (DNTC), and B cells.
(C) CD44 expression by lymph node CD4+ T cells.
(D) Expression of CD44 and CD69 on splenic B cells.
(E) Serum IgG isotype concentrations.
(F) MHC class II expression in pDCs (left) and myeloid DCs (right) from Tlr7+/y (dashed line) and Tlr72/y (solid line) mice.
(G and H) Expression of MHC class II, CD80, and CD86 in pDCs (G) and myeloid DCs (H). Data are presented as mean6 SEM. *p < 0.05; **p < 0.01;
***p < 0.0001 by Mann-Whitney U test.TLR9 is required for effective production of Abs to the
relevant DNA-containing autoantigens in SLE. This is
consistent with the impaired generation of class-
switched DNA Abs in Tlr92/2 Fcgr2b2/2 mice (Ehlers
et al., 2006).
In the absence of anti-DNA and anti-chromatin, Tlr92/2
mice developed an autoantibody repertoire shifted to-
ward other nuclear and cytoplasmic Ags, producing
novel ANA staining patterns. This is reminiscent of our
findings in Tlr92/2 F2 mice, which developed increased
anti-Sm titers in the absence of anti-DNA (Christensen
et al., 2005). Although the Tlr92/2 mice presented here
did not have elevated serum titers of anti-Sm (perhaps
due to the younger age of this cohort), ANA patterns
from these mice suggested an increase in Abs to cyto-
solic autoantigens, most likely containing RNA. It is pos-
sible that in the absence of TLR9, anti-DNA B cells per-
sist in an ignorant or anergic state. This could then allow
other autoreactive B cells to better compete for Ag or
other survival and differentiation factors, leading in
turn to a compensatory increase in RNA or Sm Abs.
The importance of TLR7 in autoimmunity was recently
suggested by the finding that the Y-linked autoimmuneaccelerator (Yaa) locus is composed of a duplication of
a 4 Mb region of the X chromosome containing TLR7,
as well as several other immune response genes (Pisit-
kun et al., 2006; Subramanian et al., 2006). Our data, a
report of genetic deficiency of TLR7 in a model of spon-
taneous SLE, complements these results. Whereas a du-
plication of this locus on the X chromosome was shown
to be sufficient to induce autoantibody formation, the
data presented here indicate that TLR7 is required for
the generation of autoantibodies to canonical RNA Ags
in vivo. Thus, our results indicate that the two major clas-
ses of autoantigens in SLE, nuclear complexes contain-
ing either DNA or RNA, are specifically controlled by
TLR9 and TLR7, respectively. TLR8 may also play
a role in the recognition of RNA autoantigens in humans
(Vollmer et al., 2005). The lack of any nuclear Abs in au-
toimmune-prone mice deficient in MyD88 further em-
phasizes the central role of TLRs and innate immunity
in directing autoantibody specificity (Lau et al., 2005).
We had previously reported an increase in certain pa-
rameters of immune activation in Tlr92/2mice of a mixed
genetic background (Christensen et al., 2005). Similarly,
Wu and Peng found increased lymphadenopathy and
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425end-organ disease in both Fas-intact and Fas-deficient
Tlr92/2 mice (Wu and Peng, 2006). We confirm those
findings of increased spleen/lymph node weight and re-
nal disease and extend those findings here in several
ways. First, we demonstrate a role for TLR9 in lupus-
induced mortality, accompanied by exacerbated skin
disease. Second, we provide new insights into the
mechanism with the description of increased pDC acti-
vation and IFN-a production in Tlr92/2 MRL/Mplpr/lpr
mice. The lack of chromatin Abs coupled with increased
IFN production and exacerbated disease pathology in
Tlr92/2 mice provides a potent example of how autoan-
tibodies and disease manifestations are not necessarily
directly linked.
Despite the analogous roles of TLR7 and TLR9 in di-
recting autoantibody specificity, we found that TLR7-
deficient lupus-prone mice were relatively protected
from autoimmune disease. In addition to decreased lym-
phocyte and pDC activation, renal disease was also
ameliorated in Tlr72/y mice. These findings suggest
that therapeutic inhibition of TLR pathways could have
beneficial effects on end-organ disease in SLE patients.
Indeed, the mitigating effect of inhibitory oligodeoxynu-
cleotides (ODN) on lupus nephritis has already been
demonstrated in mice (Dong et al., 2005; Patole et al.,
2005). Although these synthetic inhibitors were initially
shown to inhibit signaling through TLR9, the data pre-
sented here, in concert with the observation that ODNs
can also inhibit immune responses to TLR7 ligands (Bar-
Figure 7. Ameliorated Lupus Nephritis in TLR7-Deficient Mice
(A) Representative PAS-stained Tlr7+/y (left) and Tlr72/y (right) glo-
meruli.
(B) Interstitial and glomerular renal disease were scored from 0 to 4
for Tlr7+/y (black symbols, n = 20) and Tlr72/y (white symbols, n = 20)
mice.
(C) As in (B), but the sum of interstitial and glomerular scores for each
mouse was plotted to determine composite renal disease. *p < 0.05
by Mann-Whitney U test.rat et al., 2005; Lau et al., 2005), indicate that the primary
effect of these molecules in vivo may be mediated
through inhibition of TLR7. Similarly, the therapeutic ef-
fects of chloroquine in the treatment of autoimmune and
rheumatic diseases may be due to inhibition of endoso-
mal TLR activation (Vinuesa and Goodnow, 2002).
The opposing effects of TLR7 and TLR9 on immune
activation and disease severity were unexpected, since
these two receptors are expressed in similar cell types
and share downstream signaling pathways (Akira,
2003; Iwasaki and Medzhitov, 2004; Uematsu et al.,
2005). Multiple mechanisms for downregulating TLR-
induced signals have now been described (Liew et al.,
2005), and differential effects of these mechanisms on
TLR7 or TLR9 could explain the disparate knockout phe-
notypes. The adaptor protein IL-1 receptor-associated
kinase-M (IRAK-M) is induced after prolonged TLR
activation and appears to preferentially inhibit TLR9,
although its effect on TLR7 has not been determined
(Kobayashi et al., 2002). Interferon regulatory factor 4
(IRF-4) has also been identified as an inducible inhibitor
of signaling from both TLR7 and TLR9 (Negishi et al.,
2005). Induction of these regulatory mechanisms may
also allow for crossinhibition between TLR7 and TLR9
when both receptors are ligated in the same cell (Sato
et al., 2002). Additionally, a direct role for TLR9 in im-
mune regulation was recently suggested by the obser-
vation that stimulation of human pDC with CpG ODN
promotes regulatory T cell development (Moseman
et al., 2004).
The autoantibodies induced by TLR7 and TLR9 may
also contribute to the phenotypes of their respective ge-
netic knockouts. In this scenario, Abs to RNA-containing
autoantigens act as potent mediators of inflammation,
independent of DNA Abs (Alba et al., 2003; Savarese
et al., 2006). Decreased Sm-RNP Abs in Tlr72/y mice
and the appearance of additional RNA complex Abs in
Tlr92/2 mice could then account for ameliorated or ex-
acerbated disease, respectively. Indeed, we found that
several parameters of disease severity and immune ac-
tivation were correlated with Sm-RNP Abs in Tlr92/2
mice. In addition, the presence of DNA or chromatin
Abs may serve a regulatory function in SLE by promoting
clearance of cell debris and thereby reducing the avail-
ability of endogenous inflammatory mediators. Impair-
ment in the phagocytosis of apoptotic and necrotic cells
is known to induce autoimmune disease (Cohen et al.,
2002), and the protective effects of IgM DNA Abs have
been clearly demonstrated in autoimmune NZB/W
mice (Werwitzke et al., 2005).
The importance of IFN-I in autoimmune disease has
been extensively documented (Baechler et al., 2003;
Bennett et al., 2003; Santiago-Raber et al., 2003; Theo-
filopoulos et al., 2005). The ability of autoantibodies to
induce IFN-I may also contribute to divergent pheno-
typic effects in Tlr72/y and Tlr92/2 mice. Although auto-
antibodies to both DNA- and RNA-containing Ags can
induce IFN-I production by pDCs, RNA Abs may be
more potent in this regard (Barrat et al., 2005; Lovgren
et al., 2004). Moreover, Abs to RNA-containing Ags
have been correlated with increased IFN-I production
and exacerbated disease in human SLE (Kirou et al.,
2005). Enhanced IFN-I production stimulated by RNA-
containing immune complexes thus provides a potential
Immunity
426mechanistic link between the autoantibody profile, pDC
activation, and clinical disease phenotypes observed in
Tlr72/y and Tlr92/2 mice. Finally, the ability of IFN-I to
induce expression of TLR7 in B cells may allow for a
positive feedback cycle that is not present for TLR9
(Bekeredjian-Ding et al., 2005).
Our findings support the notion of two critical and po-
tentially pathologic functions of TLRs in SLE. First, acti-
vation of the innate immune system by TLRs directs the
autoantibody response to the characteristic lupus auto-
antigens; without appropriate TLR signaling, these Abs
are not generated. Second, TLRs can have a dramatic
impact on disease pathogenesis, either by promoting
disease in the case of TLR7 or by regulating disease in
the case of TLR9. These results suggest that inhibition
of TLR-signaling pathways may have therapeutic benefit
in autoimmune disease, but highlight the need for spe-
cific targeting of such therapy because of the surpris-
ingly divergent effects of different TLRs.
Experimental Procedures
Generation of Autoimmune TLR-Deficient Mice
Tlr9+/2 hybrid mice (Christensen et al., 2005) were backcrossed
eight generations to Fas-deficient, lupus-prone MRL/Mplpr/lpr mice
(Jackson Laboratory), at which point more than 99.8% of the ge-
nome was statistically derived from the MRL/Mp strain, and expres-
sion of the MHCk/k and Iga/a haplotypes derived from MRL/Mp was
verified by FACS analysis of peripheral blood cells. These Tlr9+/2
mice were then intercrossed to produce 26 Tlr9+/+ and 21 Tlr92/2 lit-
termates, which were analyzed between 13 and 14 weeks of age. For
mortality assessment, additional Tlr9+/2 mice were intercrossed to
produce a second cohort of Tlr9+/+ (n = 61, with 32 deaths during
the observation period), Tlr9+/2 (n = 29, with 16 deaths), and
Tlr92/2 (n = 44, with 35 deaths) mice, which were observed without
intervention until the time of death. Severely moribund animals were
sacrificed for humane concerns and were included as deaths in the
analysis.
Hybrid Tlr7+/2 females were generated by an initial cross of TLR7-
deficient mice (mixed C57BL/6 and 129Sv genetic background) with
male MRL/Mplpr/lpr mice. These hybrids were then backcrossed
three to six generations to male MRL/Mplpr/lpr mice, selecting only
those mice that were homozygous for the Faslpr/lpr mutation as
well as the MHCk/k and Iga/a haplotypes. After the third backcross
generation, 20 Tlr7+/y and 20 Tlr72/y male littermates were analyzed
at 16 weeks of age. For analysis of the autoantibody repertoire, se-
rum was taken from an additional 16 Tlr7+/y and 15 Tlr72/y littermates
of backcross generation 6 at 16 weeks of age. Importantly, no locus
from an undefined genetic background could be homozygous in
these mice, because every locus harbored at least one copy of the
MRL/Mp allele derived from the male parent. All animal work was ap-
proved by the Yale Institutional Animal Care and Use Committee.
Determination of Autoantibody Profiles
ANA and Crithidia luciliae immunofluorescence were performed as
previously described (Christensen et al., 2005), with serum at
1:200 dilution for ANA and 1:50 dilution for C. luciliae, and scored
by an observer blinded to the genotype of the mice. ANA images
were captured at 4003magnification with a constant 2.5 s exposure
time. For anti-nucleosome and anti-dsDNA ELISAs, polystyrene
plates were coated with either bovine histones (Sigma) or poly-
L-lysine (Sigma), respectively. Plates were then incubated with
phenol-extracted and S1 nuclease-treated dsDNA from calf thymus
(Sigma). After blocking with 1% BSA in PBS, serial dilutions of serum
from 1:200 to 1:5400 were added. Specific Abs were detected with
alkaline phosphatase-conjugated goat anti-mouse IgG (Southern
Biotech), and absorbance at 405/630nm was compared with either
PL2-3 nucleosome (Losman et al., 1992) or PL9-6 dsDNA (Losman
et al., 1993) monoclonal Abs to quantitate. Anti-Sm ELISA was per-
formed with serial dilutions of serum from 1:200 to 1:5400 as previ-
ously described (Christensen et al., 2005). Anti-Sm-RNP ELISAwas performed similarly, but plates were coated with Sm/RNP com-
plex Ag (Immunovision).
Analysis of Dendritic Cells and Global Immune Activation
Plasmacytoid and myeloid DCs were identified with anti-CD11c
(HL3, BD Biosciences) and anti-mpDCA-1 (Miltenyi Biotec). Anti-
MHC class II (M5/114.152, Biolegend), anti-CD80 (16-10A1, BD
Biosciences), and anti-CD86 (GL1, BD Biosciences) were used to as-
sess DC activation. Serum IFN-a ELISA was performed as previously
described (Christensen et al., 2005), with serum added at 1:5 dilu-
tion. Limit of detection was 0.1 ng/ml.
Spleen and lymph node cells were isolated, and T and B cell
subsets were enumerated and activation markers determined as
previously described (Christensen et al., 2005). CD69 Ab (H1.2F3,
BD Biosciences) was used as an additional marker for B cell activa-
tion. Levels of serum IgG isotypes were determined by Beadlyte
Mouse Immunoglobulin Isotyping Kit (Upstate) according to the
manufacturer’s instructions. Serum was tested at 1:250,000 or
1:200,000 dilution for TLR9 and TLR7 samples, respectively.
Determination of Clinical Disease
For skin disease, mice were scored for the extent of typical lesions
on the dorsum of the neck and back. Macroscopic surface area
was scored from 0 to 4 for affected area up to 4 cm2, with up to 1 ad-
ditional point for the presence of ear dermatitis. For kidney disease,
formalin-fixed and paraffin-embedded sections, stained with either
H&E or PAS, were scored for interstitial and glomerular disease by
two independent observers who were blinded to the genotypes of
the mice.
Supplemental Data
Two Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/25/3/417/DC1/.
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